Schedule 13D ownership disclosure

Sionna Therapeutics Inc

Common Stock · CUSIP: 829401108

Event date: 2025-02-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Atlas Venture Fund XI, L.P.Reported CIK 0001708269

    Shares: 2,886,293.00 · Class: 6.5%

  • Atlas Venture Associates XI, L.P.Reported CIK 0001780068

    Shares: 2,886,293.00 · Class: 6.5%

  • Atlas Venture Associates XI, LLCReported CIK 0001780067

    Shares: 2,886,293.00 · Class: 6.5%

  • Atlas Venture Opportunity Fund II, L.P.Reported CIK 0001885327

    Shares: 807,727.00 · Class: 1.8%

  • Atlas Venture Associates Opportunity II, LPReported CIK 0001935814

    Shares: 807,727.00 · Class: 1.8%

  • Atlas Venture Associates Opportunity II, LLCReported CIK 0001935810

    Shares: 807,727.00 · Class: 1.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-004453
Form type
SCHEDULE 13D
Filer
Atlas Venture Fund XI, L.P.
CIK
CIK 1708269
Filed
Feb 18, 2025
Reporting period
Feb 10, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub